AGN News and Press, Allergan plc From 09/13/19

Amgen ( AMGN ) and its partner Allergan ( AGN ) were able to achieve positive results in a comparative clinical study between their candidates ABP-798 and Rituxan. These positive results set up the biosimilar to potentially compete against Rituxan. This newly reported study focused on pa...

AbbVie (NYSE: ABBV) went from having a great year in 2017 to having a mediocre one in 2018 to having a downright dismal one so far in 2019. Investors have been worried for years about what would happen when the company's top-selling drug, Humira, faced biosimilar competition. That day has ar...

DUBLIN , Sept. 10, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) announ...

The FDA and European Medicines Agency have accepted for review marketing applications submitted by Allergan ( AGN -0.2% ) seeking approval for DARPin drug abicipar pegol for the treatment of neovascular age-related macular degeneration (wet AMD). The respective action dates will be in mi...

DUBLIN , Sept. 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin®...

Musings Source: Chicken Little Okay, so it’s not that bad out there (though most of us received unpleasant brokerage reports for August 2019). Furthermore, the last 12 months have been an up-and-down affair with the S&P 500 currently sitting about where it startedȂ...

Over the past years, many companies have struggled to offer the first NASH cure to the market. Billions of investments have been spent on the study and possible treatments of this complex disease. So far, no company has been able to get approval for its drug with NASH indication. But many ...

August 26 might be the single worst day in 2019 for the pharmaceutical industry. An Oklahoma judge found industry giant Johnson & Johnson (NYSE: JNJ) guilty of deceptively marketing its opioid drugs as being non-addictive despite requests from the U.S. Food and Drug Administration to s...

AbbVie ( ABBV ) is buying Allergan (AGN) for The HSR - Hart Scott Rodino Antitrust Improvement Act waiting period expired on August 26. That is important because if the HSR waiting period expires without any filings, the firms are free and clear - in this respect - to consummate the transact...

Satsuma Pharmaceuticals ( STSA ) has a product candidate at Phase 3 of development and is targeting a large market. With other competitors trading with a valuation of $0.6-1.5 billion, after the IPO, we expect the company to sell around these marks. Market participants will need to carefully r...